Bei Jing Shang Bao·2025-12-18 16:00Core Viewpoint - Increasing number of pharmaceutical companies are investing in funds to indirectly participate in promising startups and emerging technologies, enhancing their innovation and competitiveness [1][6]. Group 1: Recent Fund Investments - On December 17, 2023, Furuya Medical and Boteng Co. announced their plans to invest in funds, with Furuya Medical committing up to 93 million yuan in a private equity fund [2]. - Boteng Co. plans to acquire a portion of shares in the Yifeng Yunding Venture Capital Partnership for a nominal fee, committing to a capital contribution of 20 million yuan [2]. Group 2: Industry Trends - Several pharmaceutical companies, including Huilong Pharmaceutical, Yingke Medical, and Pianzaihuang, have also made fund investments this year, indicating a trend in the industry [4]. - Pianzaihuang has made multiple fund investments, including a 200 million yuan commitment to the Zhaoying Fund, representing 20% of its target fundraising [4][5]. Group 3: Strategic Implications - Investment in funds allows companies to access cutting-edge technologies and market dynamics, potentially leading to future business expansions and technology introductions [3][6]. - Engaging in fund investments can enhance resource sharing and collaboration with other companies and research institutions, fostering innovation and competitive advantages [5][6]. Group 4: Focus Areas of Investment - The funds targeted by these pharmaceutical companies primarily focus on biomedicine and related fields, with Boteng Co.'s investments directed towards innovative drugs and high-end medical devices [7][8]. - Furuya Medical's proposed fund, Chengde Fund, emphasizes strategic emerging industries, particularly in medical technology and digital economy, with at least 50% of investments in biomedicine and health technology [7][8]. Group 5: Structural Changes in the Industry - The trend of pharmaceutical companies investing in funds reflects a structural shift from a "product-driven" approach to a "dual-driven" model combining products and investments, indicating a deep integration of industry and capital [8].